Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5057 - 5064 of 12007 results
New York Extends Pay Equity Act to All Protected Classes
June 25, 2019| Blog| Viewpoint
Massachusetts Paid Family and Medical Leave - Summary of Final Regulations
June 24, 2019| Blog| Viewpoint
Massachusetts Paid Family and Medical Leave 2019 Regulations – Focus on the Private Plan Exemption
June 24, 2019| Blog| Viewpoint
A Summary of the Latest Changes to the New York State Human Rights Law
June 24, 2019| Blog| Viewpoint
Supreme Court Declines to Address the Question of Article III Standing to Appeal a Final Written Decision from the PTAB
June 20, 2019| Blog| Viewpoint
Brazil: Visa Exemption for United States, Canadian, Australian, and Japanese Citizens
June 19, 2019| Alert| Viewpoint
Mintz, ACLU Lead Charge to End Unlawful ICE Detentions
June 19, 2019| News
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|